Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin Effects on Urinary Proteomics in Type 2 Diabetes (DapKid)
NCT02914691Phase 4Completed
- Start
- Aug 2015
- Primary completion
- Jul 2017
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in diabetic nephropathy (DN) (2 arms). Primary endpoint: Change in Urinary Peptide Patterns (Proteomics) at 26 weeks. Started Aug 2015; status: completed.
02
Drugs
dapagliflozin
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT02914691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914691.